Amyloidosis is a rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most interesting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the efficacy of a multiple drug regimen in light-chain (AL) amyloidosis.
Systemic light-chain (AL) amyloidosis is a rare and life-threatening disease characterised by excessive light-chain depositions in the tissues and organs. The toxic light-chain paraprotein originates from clonal plasma cells or from a small B‑cell clone . The most commonly involved organs are the heart, kidneys and the liver along with the gastrointestinal tract and the peripheral and autonomic nervous systems. The pattern of organ involvement determines the clinical presentation, and the symptoms are often very unspecific: fatigue, dyspnea, ankle and leg edema, weight loss, diarrhea, obstipation and orthostatic hypotension [2, 3]. However, there are some specific but rare signs and symptoms suggesting the presence of amyloidosis. These include periorbital ecchymosis, an enlarged tongue, bilateral carpal tunnel syndromes and nail dystrophy .
Cardiac involvement is the most limiting survival factor , emphasising the need for early diagnosis. This can be accomplished with easily accessible biomarkers, mainly N‑terminal pro-brain natriuretic peptide (NT-proBNP; elevation >332 ng/l; in the absence of renal failure or atrial fibrillation) and albuminuria (>0.5 g in 24 h; in the absence of long-lasting diabetes or hypertension). These markers have been indicated in published studies as useful for risk assessment prior to therapy and for response evaluation . Furthermore, NT-proBNP and albuminuria are important biomarkers in amyloidosis screening, especially when combined with noninvasive imaging techniques like echocardiography and cardiac MRI (Figs. 1 and 2). The final diagnosis has to be verified by a mandatory biopsy, with the exception of ATTR amyloidosis (transthyretin amyloidosis, mutant and wild types). In a first step, Congo red staining has to be positive for amyloid deposits. As a next step, immunohistochemistry (IHC) has to be carried out to characterise the origin of the amyloid fibrils (; Fig. 3). Fibril typing is a crucial process within the diagnostic workflow because different types of amyloidosis need different treatment strategies. If IHC is not successful in defining the underlying protein, laser capture microdissection and mass spectroscopy should be performed [7, 8].
Problems in risk assessment and response evaluation with established biomarkers
For risk assessment before the treatment initiation and subsequent response evaluation, testing for the cardiac biomarkers NT-proBNP and troponin T is recommended, as is the measurement of systolic blood pressure [9, 10]. For the renal risk classification, proteinuria >5 g/24 h and an estimated glomerular filtration rate (eGFR) < 50 ml/min [11, 12] are of prognostic significance. The response evaluation is of great importance because organ improvement is achieved only along with haematological response. NT-proBNP is used as a main determinant of cardiac response assessment, and the US Food and Drug Administration (FDA) considers this biomarker the primary end point in clinical trials. However, NT-proBNP levels are markedly influenced by renal function, fluid overload and drug interactions that are not further specified. The optimal time points (6 or 12 months) of NT-proBNP evaluation during the course of the disease remain unclear. To address this problem, an observational prospective trial was initiated . NT-proBNP values that were analysed at 6 months did not result in a significant impact on overall survival (OS). However, evaluating NT-proBNP at 6 months resulted in a misclassification of nearly half of all potential cardiac responders. Only NT-proBNP levels captured at 12 months demonstrated prognostic significance regarding OS. This study highlights the critical importance of the timing of NT-proBNP measurements in the response assessment for clinical trials to avoid false negative results.
Evaluation of a new biomarker
Growth differentiation factor-15 (GDF-15) is a protein belonging to the transforming growth factor beta superfamily. It acts as a pleiotropic cytokine involved in the regulation of inflammatory and apoptotic pathways in injured tissues. Kastritis et al.  investigated GDF-15 levels in the peripheral blood in two independent cohorts at two different centres (Pavia and Athens). Independently of cardiac biomarkers and renal involvement, elevated GDF-15 levels >7575 pg/ml were associated with early death, shorter survival times and faster progression to dialysis.
So far, no approved (by the FDA or the European Medicines Agency, EMA) treatment is available for AL amyloidosis. Chemotherapy, proteasome inhibitors, immunomodulatory drugs (IMiD) and autologous stem cell transplantation (ASCT) are used only in an off-label manner. Some centres prefer upfront ASCT as an induction therapy, and other institutions use front-line therapy (bortezomib-based, ± IMiDs and corticosteroids)  in order to achieve organ improvement before ASCT. To address the question of which strategy provides the best outcome, bortezomib-based first-line treatment preceding ASCT was investigated in various trials, and the results were reported at the ASH meeting. Kastritis et al. presented the first prospective randomised phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for newly diagnosed patients . Alahwal et al. also presented data regarding the high effectiveness of bortezomib-containing regimens in these patient cohorts . Both trials identified bortezomib as an effective drug with profound haematological responses and organ improvement. However, the study designs and end points were different, and a direct comparison of these two trials is therefore not applicable. Interestingly, both working groups mentioned a bortezomib-based cardiac toxicity. Therefore, Alahwal et al. emphasised the importance of a nonbortezomib-based approach for patients with advanced cardiac dysfunction, i. e. melphalan/dexamethasone  to avoid additional toxicity, since these patients were found to have an inferior survival rate .
Sidana et al. introduced a trial comparing a bortezomib-containing regimen with a nonbortezomib-containing induction regimen in transplant ineligible patients with AL amyloidosis . Again, the treatment with bortezomib-based regimens resulted in better responses, including higher rates of early very good partial remission (VGPR) at 3 and 6 months. The patients achieved faster cardiac improvement and had a lower relapse rate, but no difference in OS was seen.
Two further trials with bortezomib-based induction therapy followed by ASCT were presented. Jain et al. performed a retrospective data analysis, while Minnema et al. did the data collection in a prospective designed trial. Both anlyses demonstrated an improved outcome with a better OS [20, 21]. In comparing these trials, it should be mentioned that the data collection was retrospectively in the working group of Jain et al. and in a prospective manner in Minnema’s group. However, both trials showed the beneficial effects of early ASCT after bortezomib-containing induction therapy.
The group led by Tandon investigated standard-dose versus risk-adapted melphalan conditioning on the outcome in patients undergoing front-line ASCT . Melphalan dose reduction is used in patients with older age, renal dysfunction and multiorgan involvement. The reduced dosage (140–160 mg/m2) compared to the standard dose of melphalan (200 mg/m2) resulted in a suboptimal outcome , suggesting that high-dose therapy should be limited to patients eligible for full-dose conditioning.
Biochemical patterns of relapse in AL amyloidosis
In relapsed AL amyloidosis, we face the same problems as in newly diagnosed patients: there is no standard of care and validated progression criteria and treatment recommendations are still lacking. However, since several new therapeutic options are available for plasma cell dyscrasias, new data on the effectiveness of these drugs are also being awaited in connection with AL amyloidosis. Three abstracts at the ASH meeting in 2016 were of special interest.
Tandon et al. investigated the predictors of early relapse during initial therapy . It was demonstrated that patients with early relapse are of older age with a higher prevalence of cardiac and multiorgan involvement and a higher risk stage (Mayo III and IV). Therefore, early ASCT should be an aim during the initial therapy. Milani et al. described the relapse patterns after different upfront strategies  in 259 patients. A low free light chain (FLC) burden at diagnosis and a bortezomib-containing induction regimen were associated with more durable responses. Cardiac deterioration was preceded by increasing dFLC (the difference between involved and uninvolved free light chains) in >90% of patients. An increase of >20% in dFLC should be a clear trigger to start with the relapse therapy. A “wait and see” strategy until the NT-proBNP levels increase will result in a worsened course of disease. Hwa et al. evaluated the relapse patterns after ASCT and their influence on the disease outcome . The following scenarios were evaluated: (1) hematologic relapse only, (2) organ progression only and (3) combined hematologic and organ relapse. As expected, the OS rates 4 years after ASCT were 87.8% for hematologic relapse, 63.9% for organ relapse and 56.7% (p = 0.0016) for combined organ and hematologic progression.
New therapeutic options in relapsed patients
Lagos et al. presented data from a phase II trial with bendamustine combined with dexamethasone. The regimen was well tolerated with significant success in hematologic response rates in previously treated AL amyloidosis . Cohen et al. investigated the effects of carfilzomib  in the relapse setting. Carfilzomib was feasible and effective, including in bortezomib pretreated patients, with a maximal tolerated dose (MTD) of 20 mg/m2 at the first infusion followed by a dosage of 36 mg/m2 as a 30 min infusion. However, cardiac, pulmonary and renal toxicities were documented. The close monitoring of blood pressure with the avoidance of hypertensive episodes during and after the drug infusion is recommended. NT-proBNP levels may rise without a direct correlation with progressive cardiac dysfunction. The same effect is observed during IMiD therapy. The mechanism of this phenomenon is not fully understood. Increasing NT-proBNP levels in these special settings has to interpreted with great caution. Kaufmann et al. presented data on the use of daratumumab in heavily pretreated patients with cardiac involvement . In this retrospective single centre study, antibody treatment with daratumumab was very well tolerated, resulting in rapid and significant hematologic responses. After a median time of 4 months of therapy, cardiac dysfunction improved markedly. Other mAbs with different modes of action were also investigated, as listed below.
The first additional study involved antifibrillary mAbs directed against epitopes expressed only by misfolded amyloid fibrils. Gertz et al.  investigated NEOD001 in the PRONTO trial (a phase I/II dose-escalation trial). NEOD001 is a humanised mAb binding to a cryptic epitope unique to misfolded light-chain fibrils. This epitope is exposed during misfolding and aggregation and is not targetable in regular conformation. This mAb not only disrupts amyloid fibrils, but also stimulates macrophages to phagocyte amyloid deposits. Patients eligible for this study had completed at least one round of previous therapy, with at least a partial hematologic response or better, and suffer from persistent organ dysfunction. NEOD001 was administered intravenously every 28 days to the 27 patients enrolled. No drug-related serious adverse events (AEs) were documented; the patients reported only fatigue, upper respiratory tract infection, nausea and diarrhea at a maximum of grade I or II (which was not clearly related to the study drug). No discontinuations were reported. Eight of 14 patients with cardiac involvement met the criteria for cardiac response (measured as the percentage of decrease in the pro-BNP levels), and 9 of 15 patients with renal involvement met the criteria for renal response (measured as the percentage of decrease in proteinuria in g/24 h). Because of these promising results, an expansion cohort was initiated, and the follow-up results were presented at the ASH meeting in 2016 . Forty-two additional patients were enrolled, including 16 patients with renal involvement, 15 patients with cardiac involvement and 11 patients with peripheral nerve amyloidosis. Again, no dose-limiting toxicities or discontinuations were reported. Of the cardiac-affected patients, 53% met the criteria for organ response along with 63% of renal-affected patients (expressed as the percentage of decrease in NT-proBNP or proteinuria in g/24 h); none of the patients experienced disease progression. The median times to the initial response were 2 months (cardiac) and 4 months (renal). After 9 months of treatment, 82% of patients with peripheral neuropathy achieved a response based on the Neuropathy Impairment Score in the Lower Limbs (NIS-LL score).
Edwards et al.  presented the results of a chimeric amyloid fibril reactive mAb 11-1F4 mediating amyloid destabilisation and the initiation of cell-mediated phagocytosis. The first data collected in a phase Ia trial were presented at the ASH meeting in 2015. At the ASH meeting in 2016, the follow-up results from a phase Ia/b trial were introduced . The mAb 11-1F4 was administered without severe adverse events (only fatigue, upper respiratory tract infection, nausea and diarrhea), and no dose-limiting toxicities up to an MTD of 500 mg/m2 were documented. The clinical efficacy resulted in an early and sustained organ response.
The second additional study involved an anti-SAP mAb directed against the ubiquitously present SAP (Serum Amyloid P) component. The anti-SAP mAb works only in conjunction with the small molecule drug CPHPC, which was constructed for the binding and elimination of circulating SAP molecules from the blood stream. In a second step, the anti-SAP mAb was administered intravenously. This antibody binds to the residual SAP molecules located in the tissue amyloid deposits, triggering rapid amyloid clearance through complement activation and macrophage stimulation. The first results with this new drug combination were presented at the ASH meeting in 2014. In 2015, Richards et al. published this open-labelled, single-dose escalation, phase I trial titled “Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component” in the New England Journal of Medicine . This phase I trial involved 15 patients with amyloidosis (two with AA amyloidosis, eight with AL amyloidosis, four with AFib amyloidosis and one with AApoA1 amyloidosis). The affected organs were the kidney, liver, spleen and lymph nodes. Patients with cardiac involvement were strictly excluded. No serious side effects were reported with the anti-SAP antibody and CPHPC. A response assessment was conducted after 6 weeks with a SAP scan using the 123I-SAP scintigram and a FIBRO scan. After 6 weeks, decreased liver stiffness was detected by FIBRO scan and by 123I-SAP scan. In one patient improvement in the liver function tests were measured. The same reduction was seen in the spleen and in the affected lymph nodes also documented by the SAP scan .
AL amyloidosis is a life-threatening systemic disease requiring early diagnosis with accessible biomarker measurements. For the final diagnosis, a multidisciplinary approach by specialised and experienced teams is strongly recommended. Enrolling patients in prospective, randomised international trials should still be the goal because no therapeutic standard option has been approved so far. However, an increasing number of trials with promising monoclonal antibodies and small molecules are being conducted in specialised amyloidosis centres.
Conflict of interest
H. Agis declares that she has no competing interests.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.